PXD 118490
Alternative Names: LEO 80140; PXD118490Latest Information Update: 29 Mar 2011
Price :
$50 *
At a glance
- Originator CuraGen Corporation; TopoTarget
- Class Antipsoriatics
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis; Skin disorders
Most Recent Events
- 23 Jan 2008 LEO Pharma discontinues development of PXD 118490; all rights to the compound revert to TopoTarget
- 07 Nov 2006 Preclinical trials in Psoriasis in Europe (unspecified route)
- 07 Nov 2006 Preclinical trials in Skin disorders in Europe (unspecified route)